Discontinued — last reported Q4 '17
Tapestry, Inc. Indefinite-Lived Research and Development Assets remained flat by 0.0% to $699.10M in Q1 2026 compared to the prior quarter. Year-over-year, this metric declined by 46.6%, from $1.31B to $699.10M. Over 4 years (FY 2021 to FY 2025), Indefinite-Lived Research and Development Assets shows a downward trend with a -14.5% CAGR. This decline may warrant attention — for this metric, higher values are generally preferred.
An increase indicates aggressive investment in external innovation, while a decrease may signal project completion, commercialization, or impairment charges.
This represents the value of acquired in-process research and development (IPR&D) projects that have not yet reached com...
Common in pharmaceutical and medical device sectors where M&A is a primary driver of R&D pipelines.
indefinite_lived_rd_assets| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $1.31B | $1.31B | $1.31B | $1.31B | $1.31B | $1.31B | $1.31B | $1.31B | $1.31B | $1.31B | $1.31B | $1.31B | $1.31B | $1.31B | $1.31B | $1.31B | $699.10M | $699.10M | $699.10M | $699.10M |
| QoQ Change | — | +0.0% | +0.0% | +0.0% | +0.0% | +0.0% | +0.0% | +0.0% | +0.0% | +0.0% | +0.0% | +0.0% | +0.0% | +0.0% | +0.0% | +0.0% | -46.6% | +0.0% | +0.0% | +0.0% |
| YoY Change | — | — | — | — | +0.0% | +0.0% | +0.0% | +0.0% | +0.0% | +0.0% | +0.0% | +0.0% | +0.0% | +0.0% | +0.0% | +0.0% | -46.6% | -46.6% | -46.6% | -46.6% |